Search

Shop

Donate

Your heartHealthy livingFor professionalsResearchHow you can helpAbout us
Dr Chenglong Yu smiling, wearing a black shirt.

Using genetics improve prevention of heart disease

Research directory

/

Using genetics improve prevention of heart disease

Dr Chenglong Yu, Monash University

Vanguard Grant - 2 Year

Years funded: 2025 - 2026

Using genomics to personalise heart disease prevention

Primary prevention strategies aim to deter the development of cardiovascular disease (CVD) in asymptomatic individuals. However, effective primary prevention strategies remain elusive. Low-dose aspirin has been a popular option but has recently become controversial due to its bleeding risks, especially in older adults. Recent aspirin primary prevention trials, including the ASPREE trial in Australia, have shown more harm than benefit in the general community, owing to these bleeding risks.

Targeted strategies through genomic risk profiling

However, we hypothesize that certain high-risk subgroups of the general population (identifiable through genomics) may still derive more benefit than harm from aspirin, in the primary prevention setting - with the benefits outweighing bleeding risks. If we can identify and target aspirin and other preventive interventions to these subgroups using genomics, it represents an innovative opportunity to develop and optimize “precision prevention” strategies - moving the field beyond traditional “one-size-fits-all” population methods.

Our group has shown proof-of-concept of this genomic-driven approach, by stratifying the ASPREE trial population using lipoprotein(a) genotypes, then showing that aspirin benefits outweigh the harms of bleeding in certain subgroups - based on the prevention of major adverse cardiovascular events. Our proposed Vanguard project now seeks to expand this impactful work, by using polygenic risk scores to further stratify the ASPREE population, examining other outcomes including atrial fibrillation, stroke and type 2 diabetes, whilst more rigorously investigating the genetics of bleeding risk.

Our project will also train young scientists in the highly sought-after skills of genomic epidemiology in CVD. The study is supported by an exceptionally large randomized controlled trial cohort (ASPREE), experienced investigators and robust research infrastructure at Monash University, to ensure future success, feasibility, and return on investment. The expected outcomes include high-impact research outputs, building capacity in ""genomic-driven"" clinical trials and targeted preventive strategies, and enabling the application of genomics to preventive cardiology.

Supporting breakthrough cardiovascular research in Australia
  • Looking to apply for Heart Foundation research funding? Keep an eye on our upcoming opportunities and application dates.
  • Stay informed on heart health research by subscribing to our monthly Research Connect newsletter.
  • Seeking participants for a research study? Access the Join Us Research Register to connect with a ready-to-engage pool of research participants.
  • Read more about our researchers and their projects through our Researcher Q&As.
  • Every donation to the Heart Foundation helps fund world-leading research in the fight against heart disease. Donate today.

Last updated09 May 2025

Last reviewed08 May 2025